AR and posterior cortical atrophy: While multiple genetic mechanisms mediate acquired therapeutic resistance, up to 20–25% of PCa progressing through AR targeted therapies show evidence of phenotypic plasticity, in particular transdifferentiation to neuroendocrine prostate cancer (NEPC) lineage variants [127–129].